Zivox (linezolid) coated tablets 600 mg. №10

$757.50

Manufacturer: Germany

Purpose: Inhibits bacterial protein synthesis to treat infections like pneumonia.

SKU: MED61977 Categories: , ,

Description

Zivox (Linezolid) Coated Tablets 600 mg. №10

Ingredients

Active ingredient: Linezolid 600 mg per coated tablet.

Dosage

Dosage: The usual dose of Zivox (Linezolid) is 600 mg every 12 hours, orally or intravenously, with or without food.

Indications

Indications: Zivox (Linezolid) is indicated for the treatment of infections caused by susceptible strains of certain bacteria.

Contraindications

Contraindications: Do not use Zivox (Linezolid) if you have a known hypersensitivity to linezolid or any other components of the product.

Directions

Directions: Take Zivox (Linezolid) exactly as prescribed by your healthcare provider. Do not skip doses or stop the medication early.

Scientific Evidence

Linezolid, the active ingredient in Zivox tablets, is a synthetic antibiotic that works by inhibiting bacterial protein synthesis. Studies have shown that linezolid is effective against various Gram-positive bacteria, including strains resistant to other antibiotics. Research published in the Journal of Antimicrobial Chemotherapy demonstrated the efficacy of linezolid in treating skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

Additional Information

Zivox (Linezolid) coated tablets should be stored at room temperature away from moisture and heat. It is important to complete the full course of treatment as prescribed by your healthcare provider, even if you start to feel better before the medication is finished.

Linezolid, the active ingredient in Zivox tablets, exerts its pharmacological effects by binding to the bacterial 23S ribosomal RNA of the 50S subunit, preventing the formation of a functional 70S initiation complex. This action inhibits bacterial protein synthesis, ultimately leading to bacterial cell death.

Comparative studies have shown that Zivox (Linezolid) exhibits comparable efficacy to vancomycin in the treatment of complicated skin and soft tissue infections. Additionally, linezolid has been found to have a lower incidence of adverse effects compared to other antibiotics commonly used for similar indications.